S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Economic and National Security Threats Create Lithium Bonanza (Ad)
3 Stocks Set to Lead the Nasdaq Bull Market
Buffett's firm buys more Apple, Amazon while betting on oil
Companies facing 1st tax on stock buybacks in Biden bill
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Is Ford About To Crush Workhorse Group? 
Copper More Critical than Lithium? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Economic and National Security Threats Create Lithium Bonanza (Ad)
3 Stocks Set to Lead the Nasdaq Bull Market
Buffett's firm buys more Apple, Amazon while betting on oil
Companies facing 1st tax on stock buybacks in Biden bill
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Is Ford About To Crush Workhorse Group? 
Copper More Critical than Lithium? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Economic and National Security Threats Create Lithium Bonanza (Ad)
3 Stocks Set to Lead the Nasdaq Bull Market
Buffett's firm buys more Apple, Amazon while betting on oil
Companies facing 1st tax on stock buybacks in Biden bill
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Is Ford About To Crush Workhorse Group? 
Copper More Critical than Lithium? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Economic and National Security Threats Create Lithium Bonanza (Ad)
3 Stocks Set to Lead the Nasdaq Bull Market
Buffett's firm buys more Apple, Amazon while betting on oil
Companies facing 1st tax on stock buybacks in Biden bill
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Is Ford About To Crush Workhorse Group? 
Copper More Critical than Lithium? (Ad)
TSE:ASP

Acerus Pharmaceuticals - ASP Stock Forecast, Price & News

C$2.50
-0.05 (-1.96%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
C$2.50
C$2.52
50-Day Range
C$2.25
C$3.60
52-Week Range
C$1.69
C$10.00
Volume
595 shs
Average Volume
1,112 shs
Market Capitalization
C$19.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ASP stock logo

About Acerus Pharmaceuticals (TSE:ASP) Stock

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Acerus Pharmaceuticals Trading Down 9.7 %

ASP Stock traded down C$0.27 during midday trading on Monday, hitting C$2.50. 595 shares of the company's stock were exchanged, compared to its average volume of 1,116. Acerus Pharmaceuticals has a 1-year low of C$1.69 and a 1-year high of C$10.00. The business has a 50-day simple moving average of C$2.99 and a two-hundred day simple moving average of C$1.91. The stock has a market capitalization of C$19.27 million and a PE ratio of -0.54. The company has a current ratio of 0.49, a quick ratio of 0.20 and a debt-to-equity ratio of 261.01.

Receive ASP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASP Stock News Headlines

Acerus Reports First Quarter 2022 Financial Results
Stocks in play: Acerus Pharmaceuticals Corporation.
Acerus Announces Amendment to Loan Facilities
Acerus Announces Amendments to Loan Facilities
Acerus Pharmaceuticals Corp.
Acerus Provides Update on Litigation with Recipharm
Acerus Pharmaceuticals Corp
Acerus Reports First Quarter 2021 Financial Results
See More Headlines
Receive ASP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASP Company Calendar

Today
8/16/2022
Next Earnings (Estimated)
11/14/2022

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$-3,585,000.00
Cash Flow
C$0.39 per share
Book Value
C($0.60) per share

Miscellaneous

Free Float
N/A
Market Cap
C$19.27 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Edward Gudaitis
    Pres, CEO & Director
  • Mr. Robert M. Motz
    Chief Financial Officer
  • Mr. Gavin Damstra
    Sr. VP of International Commercial
  • Dr. Christopher Sorli F.A.C.E.
    M.D., Ph.D., Chief Medical Officer
  • Mr. Kevin Thomas Hickey
    Sr. VP of US Commercial
  • Mr. Chris Witty
    Investor Relations
  • Mr. Philippe Savard
    VP, Gen. Counsel & Corp. Sec.
  • Mr. Hubert Tomasz Czerwinski
    Pres of Acerus Pharmaceuticals SRL













ASP Stock - Frequently Asked Questions

How have ASP shares performed in 2022?

Acerus Pharmaceuticals' stock was trading at C$0.03 on January 1st, 2022. Since then, ASP shares have increased by 9,900.0% and is now trading at C$2.50.
View the best growth stocks for 2022 here
.

When is Acerus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our ASP earnings forecast
.

What other stocks do shareholders of Acerus Pharmaceuticals own?
What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ASP."

How do I buy shares of Acerus Pharmaceuticals?

Shares of ASP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Acerus Pharmaceuticals' stock price today?

One share of ASP stock can currently be purchased for approximately C$2.50.

How much money does Acerus Pharmaceuticals make?

Acerus Pharmaceuticals (TSE:ASP) has a market capitalization of C$19.27 million and generates C$-3,585,000.00 in revenue each year.

How can I contact Acerus Pharmaceuticals?

The official website for the company is www.aceruspharma.com. The company can be reached via phone at 416-679-0771.

This page (TSE:ASP) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.